Publications (2)5.72 Total impact
-
Article: Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis.
[show abstract] [hide abstract]
ABSTRACT: Coxsackie virus B3 (CVB3) is believed to be a major contributor to viral myocarditis since virus-associated apoptosis plays a role in the pathogenesis of experimental myocarditis. In this study, we investigated the in vitro and in vivo antiviral activities of Phyllaemblicin B, the main ellagitannin compound isolated from Phyllanthus emblica, a Chinese herb medicine, against CVB3. Herein we report that Phyllaemblicin B inhibited CVB3-mediated cytopathic effects on HeLa cells with an IC(50) value of 7.75+/-0.15microg/mL. In an in vivo assay, treatment with 12mgkg(-1)d(-1) Phyllaemblicin B reduced cardiac CVB3 titers, decreased the activities of LDH and CK in murine serum, and alleviated pathological damages of cardiac muscle in myocarditic mice. Moreover, Phyllaemblicin B clearly inhibited CVB3-associated apoptosis effects both in vitro and in vivo. These results show that Phyllaemblicin B exerts significant antiviral activities against CVB3. Therefore, Phyllaemblicin B may represent a potential therapeutic agent for viral myocarditis.Antiviral research 09/2009; 84(2):150-8. · 3.61 Impact Factor -
Article: Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA.
[show abstract] [hide abstract]
ABSTRACT: RNA interference (RNAi) is a process by which introduced small interfering RNA (siRNA) can cause the specific degradation of mRNA with identical sequences. In this study, we applied siRNAs targeting the UL39 gene of human herpes simplex virus type 1 (HSV-1), which encodes the large subunit of ribonucleotide reductase, ICP6. Using an ICP6 expression reporter plasmid and an in vitro model of infection, we showed that synthetic siRNA silenced effectively and specifically UL39 mRNA expression and inhibited HSV-1 replication. Our work offers new possibilities for RNAi as a genetic tool for inhibition of HSV-1 replication.Archives of Virology 02/2008; 153(7):1401-6. · 2.11 Impact Factor